REG - Beximco Pharmaceut - Holdings in Company

Beximco PharmaceuticalsAnnouncement

11/04/2023 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230411:nRSK8669Va&default-theme=true

RNS Number : 8669V  Beximco Pharmaceuticals Ltd  11 April 2023

11 April 2023

 

 

BEXIMCO PHARMACEUTICALS LIMITED

 

Holdings in Company

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients, notes
that, following the announcement on 31 March 2023, two shareholders in
Bangladesh have reported a further trade between one another in the Company's
Ordinary shares, which are only tradeable in Bangladesh, to the Dhaka Stock
Exchange on 10 April 2023. This trade does not concern global depositary
receipts admitted to trading on AIM in London.

 

IFIC Securities Limited sold 4m Ordinary shares at a price of TK.135.00 per
share to New Dacca Industries Limited who bought the 4m Ordinary shares at a
price of TK.135.00 per share between 4 and 10 April 2023.

 

As a result, IFIC Securities Limited no longer owns a disclosable stake in the
Company and New Dacca Industries Limited now holds 14,345,757 Ordinary shares
representing 3.22 per cent. of the total voting rights in the Company.

 

 

For further information, please visit www.beximcopharma.com or enquire to:

Beximco Pharma

 

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, Ext.20080

 

Mohammad Asad Ullah FCS

Executive Director & Company Secretary

Tel: 880 2 58611001, Ext. 10140

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Vadim Alexandre / Abigail Wayne

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

 

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 5500 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLKZGMDDMRGFZM